US 12,421,278 B2
Immunomodulators
Tao Wang, Farmington, CT (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 17/995,196
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed Mar. 30, 2021, PCT No. PCT/US2021/024847
§ 371(c)(1), (2) Date Sep. 30, 2022,
PCT Pub. No. WO2021/202501, PCT Pub. Date Oct. 7, 2021.
Claims priority of provisional application 63/001,628, filed on Mar. 30, 2020.
Prior Publication US 2023/0151059 A1, May 18, 2023
Int. Cl. C07K 7/56 (2006.01); A61K 38/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C07D 513/22 (2006.01)
CPC C07K 7/56 (2013.01) [A61P 31/04 (2018.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01); C07D 513/22 (2013.01); A61K 38/00 (2013.01)] 5 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Rx and Ry are independently selected from CH2, C═O, (C═O)O, C═S, (C═O)NR1 or (C═S)NR2, or
Rx and Ry are both absent, and the two —NH-groups on the cyclic peptide attached to Rx and Ry connect directly to Z,
R1 is hydrogen or C1-C3 alkyl,
R2 is hydrogen or C1-C3 alkyl,
R3 is hydrogen, OH or C1-C3 alkyl,
R4 is hydrogen, OH, COOH or C1-C3 alkyl,
Z is —(CH2)n, —CH2—(CH═CH)n—CH2—, —(C═O)(C═O)—, —CHR3—(CH2)nCHR3—, —CHR3—(CH2)n—O—(CH2)n—CHR3—, aryl substituted with 0-2 R4 or

OG Complex Work Unit Chemistry
R9 is OH or O—C1-C3 alkyl and
n is an integer from 0-8.